news report
FDA Approves First Regulatory T-Cell Therapy for Stem-Cell Transplants
Tregzi improved one-year chronic GVHD-free survival to 78% in a randomized trial of 187 adults, compared with 38.4% after a standard transplant.
entities
PRECISION-T
entities
news report
Tregzi improved one-year chronic GVHD-free survival to 78% in a randomized trial of 187 adults, compared with 38.4% after a standard transplant.